

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **May 2019**

Commission File Number: **001-38480**

**IMV Inc.**

*(Name of registrant)*

**130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **IMV Inc.**

Date: May 15, 2019

By: /s/ Pierre Labbé  
Name: Pierre Labbé  
Title: Chief Financial Officer

---

Form 6-K Exhibit Index

**Exhibit  
Number**

**Document Description**

[99.1](#)

[News Release dated May 14, 2019. IMV Inc. to Present at Upcoming Investor Conferences](#)

---

**FOR IMMEDIATE RELEASE****IMV Inc. to Present at Upcoming Investor Conferences**

**Dartmouth, Nova Scotia, May 14, 2019** –IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that [IMV Chief Executive Officer Frederic Ors](#) will present at the following investor conferences in May:

**RBC Capital Markets Global Healthcare Conference**

- **Date:** Tuesday, May 21, 2019
- **Time:** 1:35 p.m. ET
- **Location:** The InterContinental New York Barclay Hotel, New York, NY

**National Bank Financials' 9<sup>th</sup> Annual Quebec Conference**

- **Date:** Wednesday, May 29, 2019
- **Time:** 9:50 a.m. ET
- **Location:** Museum Room, Shangri-la Hotel, Toronto, Ontario

**China Bio-Partnering Forum**

- **Date:** Thursday, May 30, 2019
- **Time:** 1:40 P.M. CT
- **Location:** Renaissance Schaumburg Convention Center Hotel, Chicago, IL

A copy of each meeting's presentation will be available in the [events and presentations section of IMV's website](#). A live webcast of IMV's presentation at the RBC Capital Markets conference will also be available and archived for 90 days on the [events and presentations](#) webpage.

**About IMV**

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at [www.imv-inc.com](http://www.imv-inc.com).

###

**Source: IMV Inc.**

**Investor Relations:**

Marc Jasmin, IMV Senior Director, Investor Relations and Communications

O: (902) 492-1819 ext : 1042

M: (514) 617-9481 E: [mjasmin@imv-inc.com](mailto:mjasmin@imv-inc.com)

**Media:**

Andrea Cohen, Sam Brown Inc.

T: (917) 209-7163 E: [andreacohen@sambrown.com](mailto:andreacohen@sambrown.com)

---